Ipca institutional formulations revenue rises 71% in H1 FY27

Ipca Laboratories Limited reported institutional formulations revenue of Rs 235.51 crore in H1 FY27, up 71% from Rs 137.49 crore in H1 FY26; it was the fastest-growing disclosed export formulations category as standalone export income increased 25% to Rs 1,886.78 crore.

How fast did Ipca's institutional formulations revenue grow?

Ipca's institutional formulations revenue increased 71% in the first half of financial year 2027 (H1 FY27) and 45% in the second quarter (Q2 FY27). H1 FY27 revenue reached Rs 235.51 crore, compared with Rs 137.49 crore in H1 FY26, while Q2 FY27 revenue was Rs 115.76 crore against Rs 79.66 crore a year earlier.

The H1 growth rate was 26 percentage points higher than the Q2 rate. The source does not provide product, customer, market or tender details for the institutional business, so it does not identify the specific drivers of the Rs 98.02 crore H1 increase. Ipca describes itself as a vertically integrated pharmaceutical company producing finished dosage forms and active pharmaceutical ingredients (APIs).

Which export formulation segments grew most for Ipca in H1 FY27?

Institutional formulations were Ipca's fastest-growing disclosed export formulations segment in H1 FY27, ahead of generics at 31% and branded formulations at 18%. Institutional revenue was Rs 235.51 crore, generics revenue was Rs 704.50 crore and branded formulations revenue was Rs 315.77 crore.

Generics remained the largest disclosed export formulations category by revenue despite institutional formulations posting the highest percentage growth. Generics added Rs 168.30 crore from Rs 536.20 crore in H1 FY26, exceeding the Rs 98.02 crore institutional increase and the Rs 47.14 crore branded increase from Rs 268.63 crore.

The Q2 pattern also placed institutional formulations ahead on percentage growth. Institutional revenue rose 45% to Rs 115.76 crore, while generics increased 36% to Rs 364.48 crore and branded formulations rose 19% to Rs 172.50 crore. Generics was again the largest of the three categories in the quarter.

How did formulations compare with APIs in Ipca's revenue mix?

Total formulations revenue grew faster than total API revenue for Ipca in H1 FY27, rising 20% to Rs 3,495.10 crore versus 17% growth to Rs 857.93 crore for APIs. Domestic formulations increased 13% to Rs 2,239.32 crore from Rs 1,979.91 crore, while the three disclosed export formulation categories together reached Rs 1,255.78 crore.

The API business had a different split between domestic and export activity. Domestic API revenue rose 39% to Rs 226.93 crore from Rs 163.03 crore, whereas API export revenue increased 10% to Rs 631.00 crore from Rs 571.09 crore. This compared with total formulations growth of 20% during H1 FY27.

Q2 FY27 showed a sharper contrast in API export performance. Domestic API revenue rose 56% to Rs 135.56 crore, but API exports declined 7% to Rs 298.65 crore; total formulations still increased 20% to Rs 1,809.94 crore. Standalone revenue from operations rose 19% to Rs 4,374.85 crore in H1 FY27 and 17% to Rs 2,255.61 crore in Q2 FY27.

What did the revenue mix coincide with in Ipca's profits?

Ipca reported standalone net profit after tax of Rs 760.58 crore in H1 FY27, up 34%, alongside the 20% rise in total formulations revenue. Earnings before interest, tax, depreciation and amortisation (EBITDA), before foreign-exchange gains or losses, other income and exceptional items, increased 27% to Rs 1,157.04 crore.

The stated standalone EBITDA margin was 26.45% in H1 FY27, compared with 24.68% in H1 FY26. Finance cost declined 59% to Rs 9.72 crore, while tax expense rose 46% to Rs 288.54 crore. Other income fell 23% to Rs 36.34 crore from Rs 46.94 crore.

At the consolidated level, revenue from operations increased 17% to Rs 5,698.04 crore in H1 FY27, including Rs 1,323.19 crore from subsidiaries, up 11%. Consolidated net profit after tax rose 51% to Rs 777.02 crore, and the stated consolidated EBITDA margin was 22.92%, compared with 20.12% in H1 FY26.

Q2 FY27 produced standalone EBITDA of Rs 600.22 crore, up 22%, and a standalone EBITDA margin of 26.61% against 25.46% in Q2 FY26. Consolidated revenue from operations rose 14% to Rs 2,909.94 crore, while consolidated net profit after tax increased 33% to Rs 375.13 crore.

Conclusion

Ipca's H1 FY27 revenue mix showed that institutional and generics formulations expanded faster than domestic formulations, while institutional formulations recorded the highest disclosed export-formulations growth rate at 71%. Generics supplied the largest revenue contribution among those export categories at Rs 704.50 crore, and total formulations growth of 20% exceeded the 17% rise in APIs.

The release does not disclose a forward plan, target or scheduled event for institutional formulations. Subsequent disclosures will need to show whether the H1 FY27 institutional growth rate continues, particularly alongside standalone export income of Rs 1,886.78 crore and API export revenue growth of 10% to Rs 631.00 crore.